A weekly symptom-assessment intervention led by trained lay health workers may help reduce acute care use and improve ...

Hecht, MD, discusses the phase 3 OrigAMI-3 trial for patients with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer.

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Amgen Inc. (NASDAQ: AMGN )’s thrombocytopenia drug Nplate (romiplostim) showed significant benefits in a Phase III trial for ...

A New Orleans-based cancer specialist warns that using ivermectin for treatment can have serious side effects and more.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A newly developed scoring system could enhance risk prediction and guide treatment decisions for colorectal cancer, according ...

Cuts in NIH grants and the threat of more are discouraging investment and may drive trials out of the United States.

Dr. Kristen Scarpato explains the role of genetic testing in prostate cancer care, as well as its use in determining ...

The global Gastrointestinal Devices market is expected to witness a CAGR of ~5% during the forecast period, is driven by aging populations, rising GI procedures, and colorectal cancer cases. GI ...

Patient-reported outcomes collected through an electronic health record-integrated symptom management program did not ...

About 15% of colon cancers are dMMR, which confers resistance to chemotherapy. ICIs have FDA approval for metastatic dMMR ...